25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A major obstacle to a broadly neutralizing antibody (bnAb)-based HIV vaccine is the activation of appropriate B cell precursors. Germline-targeting immunogens must be capable of priming rare bnAb precursors in the physiological setting. We tested the ability of the VRC01-class bnAb germline-targeting immunogen eOD-GT8 60mer to activate appropriate precursors in mice transgenic for human immunoglobulin loci. Despite an average frequency of at most ~1 VRC01-class precursor per mouse, we found that at least 29% of singly-immunized mice produced a VRC01-class memory response, suggesting that priming generally succeeded when at least one precursor was present. The results demonstrate the feasibility of using germline targeting to prime specific and exceedingly rare bnAb precursor B cells within a human-like repertoire.

          Related collections

          Author and article information

          Journal
          0404511
          7473
          Science
          Science
          Science (New York, N.Y.)
          0036-8075
          1095-9203
          21 March 2017
          08 September 2016
          30 September 2016
          30 September 2017
          : 353
          : 6307
          : 1557-1560
          Affiliations
          [1 ]Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California 92037, USA
          [2 ]IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California 92037, USA
          [3 ]Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California 92037, USA
          [4 ]Kymab Ltd, The Bennet Building (B930), Babraham Research Campus, Cambridge CB22 3AT, United Kingdom
          [5 ]Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
          [6 ]Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts 02129, USA
          Author notes
          [* ]To whom correspondence should be addressed. (D.R.B), burton@ 123456scripps.edu and (W.R.S), schief@ 123456scripps.edu
          [†]

          These authors contributed equally to the work

          Article
          PMC5404394 PMC5404394 5404394 nihpa855539
          10.1126/science.aah3945
          5404394
          27608668
          6f2deb31-a86f-4c53-a6a5-bd84219ec1ef
          History
          Categories
          Article

          Comments

          Comment on this article